HOTH Insider Trading

Insider Ownership Percentage: 10.56%
Insider Buying (Last 12 Months): $16,750.00
Insider Selling (Last 12 Months): $0.00

Hoth Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Hoth Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10k$0$10kTotal Insider BuyingTotal Insider Selling

Hoth Therapeutics Share Price & Price History

Current Price: $1.50
Price Change: Price Decrease of -0.08 (-5.06%)
As of 01/17/2025 05:00 PM ET

This chart shows the closing price history over time for HOTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$1.50Closing price on 01/20/25:

Hoth Therapeutics Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Hoth Therapeutics (NASDAQ:HOTH)

7.08% of Hoth Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at HOTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$49kbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$200k$0$200kTotal InflowsTotal Outflows
Hoth Therapeutics logo
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Read More on Hoth Therapeutics

Today's Range

Now: $1.50
Low: $1.47
High: $1.66

50 Day Range

MA: $1.00
Low: $0.75
High: $2.28

52 Week Range

Now: $1.50
Low: $0.58
High: $3.80

Volume

858,248 shs

Average Volume

24,643,492 shs

Market Capitalization

$10.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Who are the company insiders with the largest holdings of Hoth Therapeutics?

Hoth Therapeutics' top insider investors include:
  1. Robb Knie (CEO)
Learn More about top insider investors at Hoth Therapeutics.